KPV

Anti-Inflammatory Tripeptide Derived from α-MSH

KPV is a tripeptide composed of three amino acids: lysine, proline, and valine (K-P-V). It is derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH), retaining the potent anti-inflammatory properties of the parent molecule without the melanogenesis (skin darkening) effects.

α-MSH is a neuropeptide with broad effects on inflammation, pigmentation, and immune function. Researchers discovered that the anti-inflammatory activity of α-MSH could be traced to its C-terminal tripeptide sequence. KPV exerts similar or even more pronounced anti- inflammatory activity compared to full-length α-MSH, while being smaller, more stable, and easier to produce.

What makes KPV particularly valuable is its selectivity. Unlike α-MSH or Melanotan peptides, KPV does not stimulate melanocyte receptors. This means it delivers anti-inflammatory benefits without affecting skin pigmentation or hormone levels.

KPV is being actively researched for inflammatory bowel disease (IBD), skin conditions like psoriasis and eczema, wound healing, and systemic inflammation. Its small size allows it to be administered through multiple routes: oral, subcutaneous injection, or topical application.

For those dealing with gut inflammation, autoimmune flares, or chronic inflammatory conditions, KPV offers a targeted approach that modulates rather than suppresses immune function.

How It Works

KPV works through several distinct mechanisms to control inflammation and support tissue repair. Unlike steroids or NSAIDs that blunt inflammation system-wide, KPV works inside cells, where it helps calm overactive inflammatory signaling pathways such as NF-κB and MAPK. These pathways are commonly elevated in chronic inflammatory states. KPV is also unique in that it can be transported into intestinal and immune cells via peptide transporters, making it particularly relevant for gut-related inflammation.

NF-κB Inhibition

The primary mechanism of KPV’s anti-inflammatory effect:

• NF-κB is the “master switch” for inflammation
• KPV suppresses NF-κB activation
• This reduces expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8)
• The effect occurs inside cells after KPV is transported intracellularly

PepT1 Transporter Uptake

Unlike many peptides, KPV does not work through melanocortin receptors:

• KPV is transported into cells by PepT1, a di/tripeptide transporter
• PepT1 is expressed in intestinal epithelial cells and immune cells
• During IBD, PepT1 expression is upregulated in the colon
• This allows KPV to be taken up directly where inflammation is occurring

This explains why oral KPV is effective for gut inflammation. The same transporter that absorbs dietary tripeptides absorbs KPV and delivers it to inflamed tissues.

MAP Kinase Pathway Modulation

KPV also inhibits the MAP kinase inflammatory signaling pathway:

• Reduces inflammatory cascades at multiple levels
• Complements NF-κB inhibition for a broader effect
• Works at nanomolar concentrations (very low doses)

No Melanocortin Receptor Binding

Unlike α-MSH and Melanotan peptides:

• KPV does not bind to MC1R (no skin darkening)
• Does not have hormonal effects on appetite or libido
• “Clean” anti-inflammatory effect without off-target actions

Benefits

Gut Health and IBD

Preclinical research shows KPV can reduce inflammatory activity in intestinal tissue and support mucosal healing. This makes it of particular interest for individuals dealing with chronic gut inflammation, leaky gut patterns, or inflammatory bowel conditions. Key findings include:

• Reduces intestinal inflammation in colitis models
• Protects and repairs gut barrier integrity
• Decreases pro-inflammatory cytokine production in the colon
• Supports mucosal healing
• Potential applications for ulcerative colitis and Crohn’s disease

Helps Regulate Chronic Inflammation

KPV does not “shut down” the immune system. Instead, it helps normalize excessive inflammatory signaling, allowing the body to maintain normal immune defense while reducing unnecessary inflammatory stress.

Supports Skin and Tissue Recovery

Because inflammation drives many skin conditions, KPV has been studied for its ability to calm inflammatory responses in skin models. This has led to interest in its use for inflammatory skin issues and post-injury tissue repair. Topical and systemic applications include:

• Reduces inflammation in psoriasis, eczema, and dermatitis
• Accelerates wound healing
• Decreases redness and irritation
• Promotes tissue repair without scarring
• Does not cause skin pigmentation changes

Antimicrobial and Barrier Support Properties

Laboratory studies suggest KPV and related peptides may exhibit antimicrobial activity and help protect tissue barriers—an important factor in both gut and skin health. KPV retains antimicrobial properties from α-MSH:

• Active against Staphylococcus aureus
• Active against Candida albicans
• Enhances (not reduces) pathogen killing by neutrophils
• Reduces infection risk during wound healing

Systemic Inflammation

Broader anti-inflammatory effects include:

• May benefit autoimmune conditions
• Modulates immune response without suppressing it
• Reduces oxidative stress
• Potential applications for arthritis, allergic asthma, and other inflammatory conditions

Wound Healing

Enhanced tissue repair properties include:

• Speeds wound closure
• Reduces scar formation
• Supports collagen organization
• Effective in burns and chronic ulcers

What the Science Shows

KPV has substantial preclinical evidence, particularly for inflammatory bowel disease.

Dalmasso et al. (2008) – Gastroenterology

Landmark study on the KPV mechanism:

• Nanomolar concentrations of KPV inhibit NF-κB and MAP kinase pathways
• Effect mediated through the PepT1 transporter (not melanocortin receptors)
• Oral KPV reduced colitis severity in two mouse models (DSS and TNBS)
• Decreased pro-inflammatory cytokine expression

Xiao et al. (2017) – Molecular Therapy

Advanced oral delivery study:

• Hyaluronic acid-functionalized nanoparticles loaded with KPV
• Targeted delivery to colitis tissue
• Combined effects: accelerated mucosal healing and reduced inflammation
• Nanoparticle delivery enhanced therapeutic efficacy

Hiltz & Lipton (1989) – FASEB Journal

Early discovery work:

• Demonstrated anti-inflammatory activity of the C-terminal α-MSH fragment
• Established KPV as the active anti-inflammatory sequence
• Showed antipyretic (fever-reducing) effects

Brzoska et al. (2008) – Endocrine Reviews

Comprehensive review of α-MSH peptides:

• KPV exerts “similar or even more pronounced anti-inflammatory activity” than full α-

MSH

• Effective in animal models of contact dermatitis, arthritis, colitis, and asthma
• Low toxicity and good safety profile
• Promising candidate for immune-mediated inflammatory diseases

Antimicrobial Studies

• α-MSH peptides enhanced neutrophil killing of pathogens
• KPV showed direct activity against S. aureus and C. albicans
• Candidacidal activity linked to increased cellular cAMP

Dosing Protocol

KPV can be administered through multiple routes depending on the target condition. KPV dosing is based primarily on preclinical research and clinical protocols. Human trial data remain limited, but the peptide appears well tolerated across routes and doses.

Subcutaneous Injection (Systemic)

Purpose Dose Frequency Duration

General inflammation 200 to 400 mcg Once daily Until improvement

Acute flares 400 mcg Once daily 7 to 14 days

Chronic management 200 mcg Once daily 4 to 8 weeks

Subcutaneous injection provides a systemic anti-inflammatory effect with good bioavailability.

Oral Administration (Gut Focus)

Purpose Dose Frequency Duration

IBD/colitis support 250 mg Twice daily 4 to 8 weeks

Gut barrier support 250 mg Once daily Ongoing

Leaky gut protocol 250 mg Twice daily 30 to 60 days

Oral KPV is absorbed by PepT1 in the gut, making it effective for intestinal inflammation.

Topical Application (Skin)

Purpose Concentration Frequency

Wound healing 0.1% cream Twice daily

Eczema/psoriasis 0.1% cream Twice daily

Acne 0.005 to 0.1% Twice daily

Topical KPV has poor penetration through intact skin but works well on compromised or inflamed skin.

Combination Protocols

KPV pairs well with other peptides:

• KPV + BPC-157: Anti-inflammatory + tissue repair
• Oral KPV/BPC-157 capsules (500 mcg/500 mcg): One capsule daily for gut healing

Draw Volumes by Vial Size

5 mg Vial (2 mL reconstitution = 2,500 mcg/mL)

Dose Volume Units on Syringe

200 mcg 0.08 mL 8 units

300 mcg 0.12 mL 12 units

400 mcg 0.16 mL 16 units

10 mg Vial (3 mL reconstitution = 3,333 mcg/mL)

Dose Volume Units on Syringe

200 mcg 0.06 mL 6 units

300 mcg 0.09 mL 9 units

400 mcg 0.12 mL 12 units

At 300 mcg daily, a 10 mg vial provides approximately 33 doses.

Reconstitution Instructions

1. Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol swab. 2. Draw 2 mL (for a 5 mg vial) or 3 mL (for a 10 mg vial) of bacteriostatic water into a sterile syringe. 3. Insert the needle through the rubber stopper at an angle. 4. Direct the stream of water down the inside wall of the vial. 5. Allow the peptide to dissolve without shaking. 6. Gently swirl if needed until the solution is clear. 7. Label the vial with the date and concentration.

KPV dissolves readily, and the solution should be clear and colorless.

Side Effects and Cautions

Reported Side Effects

KPV has an excellent safety profile with minimal reported side effects:

• Mild injection site irritation (subcutaneous)
• Transient skin redness (topical)
• Occasional GI upset at higher oral doses
• Generally well tolerated across all routes

Advantages Over Traditional Anti-Inflammatories

• Does not suppress immune function like steroids
• No NSAID-related GI or cardiovascular risks
• Does not cause skin pigmentation (unlike α-MSH)
• No hormonal effects on appetite or libido

Lack of Long-Term Human Data

• Most research is preclinical (animal studies)
• Long-term safety in humans is not fully established
• Use with clinical oversight is recommended

Contraindications and Precautions

Who Should Avoid KPV

• Pregnant or breastfeeding women (insufficient safety data)
• Those with known hypersensitivity to KPV or related peptides

Use with Care

• Individuals with autoimmune conditions (consult a healthcare provider)
• Those on immunosuppressive medications
• Anyone with active malignancy

Comparison to Similar Compounds

Compound Anti-Inflammatory Melanogenesis Route Options

KPV Primary effect None Oral, SubQ, Topical

α-MSH Yes Yes Injection

BPC-157 Moderate None Oral, SubQ

LL-37 Yes + Antimicrobial None SubQ, Topical

KPV vs. BPC-157

BPC-157 focuses on tissue and tendon repair, while KPV is stronger for inflammation control. They are often combined for comprehensive gut healing.

KPV vs. α-MSH

α-MSH has broader hormonal effects, including skin darkening. KPV is the “clean” fragment targeting inflammation only.

Success Tips

Match Route to Target

• Gut inflammation: Oral KPV reaches the intestine directly
• Systemic inflammation: Subcutaneous injection provides a broader effect
• Skin conditions: Topical application on affected areas

Be Patient

Most users report symptom improvement within 3 to 7 days. Gut and skin benefits tend to appear first. Full effects may take 2 to 4 weeks.

Consider Cycling

Occasional breaks after 30 to 60 days of continuous use may help maintain effectiveness. Protocols often use 2-week cycles with breaks.

Combine Strategically

KPV works well in combination with tissue repair peptides:

• BPC-157: For gut healing and tissue repair
• TB-500: For broader regeneration support
• GHK-Cu: For skin and collagen support

Storage and Handling

Before Reconstitution

• Store lyophilized powder at −20°C for long-term stability
• Short-term storage at 2°C to 8°C is acceptable
• Protect from light

After Reconstitution

• Refrigerate at 2°C to 8°C
• Use within 30 days
• Protect from light
• Discard if solution becomes cloudy or discolored

Legal Status

United States: KPV is not FDA-approved. It is sold as a research peptide labeled “for research use only.” It is not legally recognized as a supplement or therapy.

International: Similar research-only status in most jurisdictions.

Frequently Asked Questions

Can I take KPV orally for gut issues? Yes. KPV is absorbed by the PepT1 transporter in the intestine, making oral administration effective for gut inflammation. This is one of KPV’s unique advantages over many other peptides.

Will KPV darken my skin like Melanotan? No. KPV does not bind to melanocortin receptors responsible for melanogenesis. It provides anti-inflammatory benefits without any skin pigmentation effects.

How is KPV different from steroids? Steroids suppress the immune system broadly. KPV modulates inflammation without suppressing immune function. This means you get anti-inflammatory effects while maintaining normal immune defense.

Can I use KPV with BPC-157?

Yes. KPV and BPC-157 are commonly combined. KPV handles inflammation while BPC-157 promotes tissue repair. Oral combination capsules are available for gut healing protocols.

How quickly will I see results? Most users report improvement within 3 to 7 days. Gut and skin benefits typically appear first. Full effects may take 2 to 4 weeks of consistent use.

References

8. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166–178. 9. Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy. 2017;25(7):1628–1640. 10. Luger TA, Brzoska T. α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases. 2007;66(Suppl 3):iii52– iii55. 11. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB Journal. 1989;3(11):2282–2284. 12. Brzoska T, Luger TA, Maaser C, et al. α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects In Vitro and In Vivo. Endocrine Reviews. 2008;29(5):581–602.